Log In
Print
BCIQ
Print
Print this Print this
 

BCI-838

  Manage Alerts
Collapse Summary General Information
Company Taisho Pharmaceutical Holdings Co. Ltd.
DescriptionOral prodrug of BCI-632, a metabotropic glutamate receptor subtype 2 (mGluR2; GRM2) and mGluR3 antagonist
Molecular Target Metabotropic glutamate receptor subtype 2 (mGluR2) (GRM2) ; Metabotropic glutamate receptor subtype 3 (mGluR3) (GRM3)
Mechanism of Action 
Therapeutic Modality 

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Get a free BioCentury trial today